Evaluation of Liquid Hydrogen/Hydrogen Peroxide Propellant Combination for Advanced Launch Vehicle Upper Stage
Aerospace · 26.12.2025 · 13 (1) · 23
DOI: 10.3390/aerospace13010023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aerospace, online erschienen am 26.12.2025. Verfasst von Min-Seon Jo und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korean government, Ministry of Education.
Abstract (Originalsprache)
Hydrogen peroxide (H2O2) is a dense, storable oxidizer, but its suitability for high-energy upper stages is limited. This study evaluates liquid hydrogen–hydrogen peroxide (LH2/H2O2) as an alternate propellant using KSLV-II as the reference vehicle. Propulsion performance was analyzed with NASA CEA and RPA, while staging and MER methods assessed system-level effects. The results show that the specific impulse decreases from 465 s (LH2/LOX) to 372~382 s with H2O2, but structural efficiency improves as the coefficient drops from 0.162 to 0.099~0.102. The payload capacity increases compared with Jet A-1/LOX yet remains below that of LOX. These findings clarify both the advantages and limitations of H2O2 as an upper-stage oxidizer.
Förderung
- Korean government
- Ministry of Education
Zitieren
APA
Jo, M., & Choi, J. (2025). Evaluation of Liquid Hydrogen/Hydrogen Peroxide Propellant Combination for Advanced Launch Vehicle Upper Stage. Aerospace, 13(1), 23. https://doi.org/10.3390/aerospace13010023
Vancouver
Jo M, Choi J. Evaluation of Liquid Hydrogen/Hydrogen Peroxide Propellant Combination for Advanced Launch Vehicle Upper Stage. Aerospace. 2025;13(1):23. doi:10.3390/aerospace13010023
BibTeX
@article{Jo2025,
author = {Jo, Min-Seon and Choi, Jeong-Yeol},
title = {Evaluation of Liquid Hydrogen/Hydrogen Peroxide Propellant Combination for Advanced Launch Vehicle Upper Stage},
journal = {Aerospace},
year = {2025},
volume = {13},
number = {1},
pages = {23},
doi = {10.3390/aerospace13010023}
}
EUVIMED